ABSTRACT
Objective Following a Mediterranean diet (MedDiet) and being physically active decrease cardiovascular risk. However, their individual and combined effects on atherothrombosis biomarkers are unexplored.
Approach and Results In 358 random volunteers from the PREDIMED trial (Prevención con Dieta Mediterránea), we assessed the 1-year effects of an intervention with MedDiet, enriched with virgin olive oil (MedDiet-VOO; N=120) or nuts (MedDiet-Nuts; N=119) versus a low-fat control diet (N=119), on atherothrombosis markers. In a secondary, observational approach, we studied the associations of 1-year changes in MedDiet adherence, physical activity (PA) levels, and their combination, with 1-year differences in atherothrombosis biomarkers. The MedDiet-VOO intervention increased HDL platelet activating factor-acetylhydrolase activity by 8.2% (95% CI: 0.92; 15.6) and decreased HDL-bound α1-antitrypsin levels by 5.8% (95% CI: −11.6; −0.046) versus control diet. The MedDiet-Nuts intervention reduced non-esterified fatty acid levels by 9.1% (95% CI: −18.0; −0.19) relative to control. Only the low-fat diet was associated with increases in platelet factor-4 and prothrombin factor1+2 concentrations versus baseline (P=0.012 and P=0.003, respectively). Increments in MedDiet adherence (+1 point) were associated with lower fibrinogen levels (−1.8%, 95% CI: −3.38; −0.17). Increases in PA (+100 METs·min/d) were linked to lower prothrombin factor1+2 (−5.2%, 95% CI: −10.4; −0.077) and plasminogen activator inhibitor-1 concentrations (−3.0%, 95% CI: −5.93; −0.12). Finally, 1-point increments in MedDiet adherence plus 100 METs·min/d of PA were related to lower D-dimer levels (−1.52%, 95% CI: −3.10; 0.026; P-interaction=0.047).
Conclusions Following a MedDiet and increasing PA were associated with improvements in atherothrombosis biomarkers in high cardiovascular risk individuals.
HIGHLIGHTS
1 year of intervention with MedDiet enhanced HDL antithrombotic properties and decreased the levels of non-esterified fatty acids in high cardiovascular risk individuals.
The low-fat control diet was the only intervention linked to increments in the levels of platelet factor-4 and prothrombin activation relative to baseline.
Increases in MedDiet adherence were associated with decrements in fibrinogen levels, increments in PA were linked to decreases in prothrombin fragment 1+2 and PAI-1 levels, and combined increases in MedDiet adherence and PA were related to improvements in D-dimer concentrations.
Competing Interest Statement
X.P. reports personal fees from Abbott, Esteve, Lacer, Rubio, and Sanofi. J.S.-S. reports to be a board member and grants from the International Nut and Dried Fruit Foundation; to be a member of the Executive Committee and personal fees from Instituto Danone Spain; personal fees from Aguas Font Vella Lanjarón, and Danone S.A; and grants from Eroski Distributors. F.A. reports personal fees from Menarini and AstraZeneca. E.R. reports personal fees and non-financial support from Merck, Sharp & Dohme; grants, personal fees, and non-financial support from the California Walnut Commission; grants and personal fees from Sanofi; personal fees and non-financial support from Danone; personal fees and non-financial support from Ferrer International; personal fees from Amarin; and grants from Pfizer. R.E. reports grants from Bicentury SA, Cerveza y Salud, Grand Fountaine, and Novartis SA; and personal fees from Brewers of Europe, FIVIN, Fundación Cerveza y Salud, Lilly Laboratories, and Wine and Culinary International Forum. The rest of the authors have nothing to disclose.
Clinical Trial
ISRCTN35739639
Funding Statement
This work was supported by grants of Instituto de Salud Carlos III [OBN17PI02, PIE14/00045_INFLAMES, CB06/03/0019, CB06/03/0028, CD17/00122 (A.H.), and JR17/00022 (O.C.)], and Agència de Gestió d’Ajuts Universitaris i de Recerca (2017 SGR 222). CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
Considering that we do not have the explicit written consent of the study volunteers to yield their deidentified data at the conclusion of the study, individual participant data cannot be shared. The study protocol is available in the main publication of the study1 and in the study website (http://www.predimed.es/uploads/8/0/5/1/8051451/_1estr_protocol_olf.pdf), and a summary of the dietary intervention is also available in Supplemental Methods.
Abbreviations
- HDL
- high-density lipoprotein
- MedDiet
- Traditional Mediterranean Diet
- MedDiet-Nuts
- Traditional Mediterranean Diet enriched in nuts
- MedDiet-VOO
- Traditional Mediterranean Diet enriched in virgin olive oil
- NEFA
- non-esterified fatty acids
- PA
- physical activity
- PAF-AH
- platelet activating factor-acetylhydrolase
- PAI1
- plasminogen activator inhibitor-1
